ClinicalTrials.gg
RecruitingNCT07518147Updated Nov 2, 2026

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

A Phase 3 interventional study of BL-M05D1 and Paclitaxel in Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by Biokin (Shanghai) Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 2, 2026Eligibility revisedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,186 studies in Stomach Neoplasms with a site in China — 482 open to participants now, 559 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
145th of 883
438 · median 87
Started
2026
with 94 others
Phase 3
122 of 1,186
33 open now
Primary completion
2029-12
later than 533 of 558 live
Registered
1,114th of 1,186
by date

Among the 1,186 studies in Stomach Neoplasms with a site in China, this one is the 145th largest by planned enrollment of the 883 interventional ones that give a count, is one of 95 that started in 2026, is one of 122 in phase 3, reaches primary completion later than 533 of the 558 other live ones, and was the 1,114th registered.

Stomach Neoplasms

3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

482 of the 1,186 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

477 more — sign in →

All 482 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,186 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M05D1 in patients with Claudin (CLDN) 18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC) who have received prior first-line treatment.

Read the detailed description

In this trial, the experimental group receives BL-M05D1, with each treatment cycle lasting 3 weeks. The control group receives investigator-selected treatment regimens: paclitaxel, docetaxel, or irinotecan.

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form and comply with protocol requirements;
  2. No gender restriction;
  3. Age: ≥18 years and ≤75 years;
  4. Expected survival time ≥3 months;
  5. confirmed locally advanced unresectable or gastric or gastroesophageal junction adenocarcinoma;
  6. Patients who have failed prior standard treatment, with evidence of definitive radiological progression;
  7. Able to provide archived or fresh tumor tissue;
  8. Have radiologically evaluable lesions according to 1.1 criteria;
  9. (ECOG) performance status of 0 or 1;
  10. Toxicity from prior antitumor therapy has recovered to ≤Grade 1 as defined by v6.0;
  11. No severe cardiac dysfunction, ≥50%;
  12. Organ function levels must meet the requirements;
  13. Urine protein ≤1+ or \<1000 mg/24 h;
  14. For premenopausal women of , a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy testing must exclude pregnancy, and the participant must not be breastfeeding; all enrolled trial participants and their partners must agree to use adequate highly effective throughout the entire treatment period and for 7 months (women) and 4 months (men) after treatment completion, and it is recommended that additional contraceptive methods be used concurrently.

Exclusion criteria

Exclusion Criteria:

  1. Prior anti-tumor therapy;
  2. Positive expression in tumor tissue;
  3. History of severe cardiovascular and cerebrovascular diseases;
  4. prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
  5. Any thrombotic event within 6 months before randomization;
  6. Active diseases and inflammatory diseases;
  7. Diagnosis of other within 3 years before the first dose;
  8. Hypertension poorly controlled with two antihypertensive drugs;
  9. History of interstitial lung disease (ILD) treated with hormones, etc.;
  10. Concurrent pulmonary diseases resulting in clinically severe respiratory impairment;
  11. Severe infection, etc. occurring within 4 weeks before the first use of the study drug;
  12. Patients with poorly controlled blood glucose;
  13. Patients with active central nervous system ;
  14. Patients with massive serous cavity effusion, or serous cavity effusion with symptoms, or poorly controlled serous cavity effusion;
  15. Imaging examinations indicating that the tumor has invaded or encased major vessels in the chest, neck, pharynx, etc.;
  16. Patients with a history of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any component of BL-M05D1;
  17. Prior organ transplantation or hematopoietic stem cell transplantation;
  18. Positive antibody, active tuberculosis, active virus infection, or active virus infection;
  19. Pregnant or breastfeeding women;
  20. Esophageal or gastric varices requiring intervention within the past three months, etc.;
  21. History of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection, etc.;
  22. Patients with other severe physical or laboratory abnormalities or poor compliance, etc., which may increase the risk of participating in the study, or interfere with the study results, and patients deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
438 participants (estimated)

Study arms

  • Experimental
    BL-M05D1

    Participants receive BL-M05D1 in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: BL-M05D1

  • Active comparator
    Paclitaxel or Docetaxel or Irinotecan hydrochloride

    Participants receive Paclitaxel or Docetaxel or Irinotecan hydrochloride in the first cycle. Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: Paclitaxel · Drug: Docetaxel · Drug: Irinotecan hydrochloride

Interventions

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 4 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 2 weeks.

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.

    Time frame: Up to approximately 24 months

  2. Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).

    Time frame: Up to approximately 24 months

  3. Disease Control Rate (DCR)

    Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.

    Time frame: Up to approximately 24 months

  4. Duration of Response (DOR)

    Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.

    Time frame: Up to approximately 24 months

  5. Time to Response (TTR)

    Time to Response (TTR) is defined as the time from randomization to the first documented response (CR or PR) according to RECIST v1.1 criteria.

    Time frame: Up to approximately 24 months

  6. Treatment Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M05D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M05D1.

    Time frame: Up to approximately 24 months

  7. Cmax

    Cmax is defined as the maximum observed drug concentration in plasma after administration.

    Time frame: Up to approximately 24 months

  8. Tmax

    Tmax is defined as the time required to reach the maximum drug concentration in plasma following drug administration.

    Time frame: Up to approximately 24 months

  9. T1/2

    T1/2 is defined as the time required for the plasma concentration of a drug to decrease by 50% during the elimination phase.

    Time frame: Up to approximately 24 months

  10. AUC0-t

    AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.

    Time frame: Up to approximately 24 months

  11. CL (Clearance)

    Clearance (CL) is the volume of plasma from which a drug is completely removed per unit time.

    Time frame: Up to approximately 24 months

  12. Ctrough

    Ctrough is defined as the lowest serum concentration prior to the next dose will be administered.

    Time frame: Up to approximately 24 months

  13. Anti-drug antibody (ADA)

    Frequency of anti-BL-M05D1 antibody (ADA) will be investigated.

    Time frame: Up to approximately 24 months

  14. Neutralizing Antibody(NAb)

    Frequency of anti-BL-M05D1 neutralizing antibodies will be investigated.

    Time frame: Up to approximately 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's planned 43 months is close to that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 8, 2026
StartActual
May 15, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
9 inclusion criteria edited, 1 removed; 15 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedVoluntarily sign the informed consent form and comply with the protocol requirements;
  • EditedNo gender restrictionsrestriction;
  • EditedPatients who have failed prior first-line standard therapy must havetreatment, with evidence of radiographic cleardefinitive radiological progression;
  • EditedAbilityAble to provide archived or fresh tumor tissue;
  • ChangedBefore Must have at least one measurable lesion as defined by RECIST v1.1;Now Have radiologically evaluable lesions according to RECIST 1.1 criteria;
  • EditedToxicity from prior anti-tumorantitumor therapy must havehas recovered to ≤ Grade 1 as defined by NCI-CTCAE v5v6.0;
  • EditedNo severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%;
  • RemovedCoagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × upper limit of normal (ULN);
  • EditedUrine protein ≤21+ or <1000 mg/24h24 h;
  • EditedFor premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with; serum pregnancy test negativetesting must exclude pregnancy, and the participant must not be non-lactatingbreastfeeding; all enrolled patients (regardless of male or female)trial participants and their partners must takeagree to use adequate barrier contraceptive measureshighly effective contraception throughout the entire treatment period and for 67 months (women) and 4 months (men) after treatment completion, and it is recommended that additional contraceptive methods be used concurrently.
Exclusion criteria
  • EditedPrior anti-tumor treatmenttherapy;
  • EditedHistory of severe cardiovascular orand cerebrovascular diseasediseases;
  • EditedProlonged QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
  • ChangedBefore Unstable thrombotic events requiring therapeutic intervention within 6 months prior to screening;Now Any thrombotic event within 6 months before randomization;
  • EditedDiagnosis of another malignancyother malignancies within 3 years prior tobefore the first dose;
  • EditedHypertension poorly controlled bywith two antihypertensive medicationsdrugs;
  • EditedHistory of interstitial lung disease (ILD) requiring hormone therapytreated with hormones, etc.;
  • EditedConcurrent pulmonary diseasediseases resulting in clinically severe respiratory impairment;
  • ChangedBefore Infection requiring clinical intervention within 2 weeks prior to randomization;Now Severe infection, etc. occurring within 4 weeks before the first use of the study drug;
  • EditedPatients with poorly controlled blood glucose levels;
  • EditedPatients with largemassive serous cavity effusionseffusion, symptomaticor serous cavity effusionseffusion with symptoms, or poorly controlled serous cavity effusionseffusion;
  • EditedImaging findingsexaminations indicating that the tumor invasionhas invaded or encasement ofencased major blood vessels such as those in the chest, neck, or pharynxpharynx, etc.;
  • EditedHistoryPatients with a history of allergic reactionsallergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of BL-M05D1;
  • EditedPositive for human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  • RemovedActive infection requiring systemic treatment;
  • EditedPresence ofPatients with other serioussevere physical or laboratory abnormalities, or poor compliance, etc., which may increase the risk of participating in the study, or interfere with the study results, or make the patientand patients deemed unsuitable for participation in thethis study as judged by the investigator.
Nov 2, 2026
Secondary outcomes
7 added
What changed in the outcomes
  • AddedCmaxTime frame: Up to approximately 24 months
  • AddedTmaxTime frame: Up to approximately 24 months
  • AddedT1/2Time frame: Up to approximately 24 months
  • AddedAUC0-tTime frame: Up to approximately 24 months
  • AddedCL (Clearance)Time frame: Up to approximately 24 months
  • AddedCtroughTime frame: Up to approximately 24 months
  • AddedNeutralizing Antibody(NAb)Time frame: Up to approximately 24 months
Nov 2, 2026
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.→Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Eligibility 9 inclusion criteria edited, 1 removed; 15 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedVoluntarily sign the informed consent form and comply with the protocol requirements;
    • EditedNo gender restrictionsrestriction;
    • EditedPatients who have failed prior first-line standard therapy must havetreatment, with evidence of radiographic cleardefinitive radiological progression;
    • EditedAbilityAble to provide archived or fresh tumor tissue;
    • ChangedBefore Must have at least one measurable lesion as defined by RECIST v1.1;Now Have radiologically evaluable lesions according to RECIST 1.1 criteria;
    • EditedToxicity from prior anti-tumorantitumor therapy must havehas recovered to ≤ Grade 1 as defined by NCI-CTCAE v5v6.0;
    • EditedNo severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%;
    • RemovedCoagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × upper limit of normal (ULN);
    • EditedUrine protein ≤21+ or <1000 mg/24h24 h;
    • EditedFor premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with; serum pregnancy test negativetesting must exclude pregnancy, and the participant must not be non-lactatingbreastfeeding; all enrolled patients (regardless of male or female)trial participants and their partners must takeagree to use adequate barrier contraceptive measureshighly effective contraception throughout the entire treatment period and for 67 months (women) and 4 months (men) after treatment completion, and it is recommended that additional contraceptive methods be used concurrently.
    Exclusion criteria
    • EditedPrior anti-tumor treatmenttherapy;
    • EditedHistory of severe cardiovascular orand cerebrovascular diseasediseases;
    • EditedProlonged QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
    • ChangedBefore Unstable thrombotic events requiring therapeutic intervention within 6 months prior to screening;Now Any thrombotic event within 6 months before randomization;
    • EditedDiagnosis of another malignancyother malignancies within 3 years prior tobefore the first dose;
    • EditedHypertension poorly controlled bywith two antihypertensive medicationsdrugs;
    • EditedHistory of interstitial lung disease (ILD) requiring hormone therapytreated with hormones, etc.;
    • EditedConcurrent pulmonary diseasediseases resulting in clinically severe respiratory impairment;
    • ChangedBefore Infection requiring clinical intervention within 2 weeks prior to randomization;Now Severe infection, etc. occurring within 4 weeks before the first use of the study drug;
    • EditedPatients with poorly controlled blood glucose levels;
    • EditedPatients with largemassive serous cavity effusionseffusion, symptomaticor serous cavity effusionseffusion with symptoms, or poorly controlled serous cavity effusionseffusion;
    • EditedImaging findingsexaminations indicating that the tumor invasionhas invaded or encasement ofencased major blood vessels such as those in the chest, neck, or pharynxpharynx, etc.;
    • EditedHistoryPatients with a history of allergic reactionsallergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of BL-M05D1;
    • EditedPositive for human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
    • RemovedActive infection requiring systemic treatment;
    • EditedPresence ofPatients with other serioussevere physical or laboratory abnormalities, or poor compliance, etc., which may increase the risk of participating in the study, or interfere with the study results, or make the patientand patients deemed unsuitable for participation in thethis study as judged by the investigator.
    Secondary outcomes 7 added
    What changed in the outcomes
    • AddedCmaxTime frame: Up to approximately 24 months
    • AddedTmaxTime frame: Up to approximately 24 months
    • AddedT1/2Time frame: Up to approximately 24 months
    • AddedAUC0-tTime frame: Up to approximately 24 months
    • AddedCL (Clearance)Time frame: Up to approximately 24 months
    • AddedCtroughTime frame: Up to approximately 24 months
    • AddedNeutralizing Antibody(NAb)Time frame: Up to approximately 24 months
    Sponsor Sichuan Baili Pharmaceutical Co., Ltd.→Biokin (Shanghai) Biopharmaceutical Co., Ltd.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07518147
Lead sponsor
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
May 15, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
15013238943

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1

Start the discussion